Bayer AG’s betaferon multiple sclerosis treatment helped patients live longer when taken soon after the onset of the disease in a study researchers said is the first to show such a drug extends patients’ lives.
Patients who got betaferon soon after diagnosis were 39 percent less likely to be dead more than two decades later than those who were given a placebo, researchers said in a study released today at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Gothenburg, Sweden.
Long-term data establishing effectiveness and safety may help differentiate older MS treatments like the Bayer drug, approved in the U.S. in 1993, from newer treatments such as Novartis AG’s pill Gilenya, lead researcher Anthony Reder, director of the University of Chicago MS Clinic, said in a conference call with reporters.
“The number I’m giving you today is a bird in the hand, here, with a very prominent effect,” Reder said.
Merck KGaA’s Rebif and Biogen Idec Inc.’s Avonex, both beta interferons in the same family as the Bayer drug, might also be expected to show a similar survival benefit, Reder said. Merck, based in Darmstadt, Germany, and Cambridge, Massachusetts-based Biogen Idec haven’t tested survival over such a long time window, he said. The data isn’t likely to come up in a shorter trial because patients may live for a long time with the debilitating neurological disease, he said.
With funding from Bayer, based in Leverkusen, Germany, Reder and other researchers tracked down all but six of the 372 patients who participated in a betaferon trial in 1988, before the drug was approved in the U.S. or Europe.
***********************************************************
"Providing You with 'MS Views and News', is what we do"
Keep Informed and up-to-date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
2 comments:
What's the benefit of long life with extreme disabilities!!!
Last week I googled "buy fingolimod" and got several wholesale outlets that sell fingolimod for non-human research (so more applications can be found). At one company it costs $42.00 for 50mg. The Gilenya website says that the pills would be 0.05mg each day. That's about 15mg a month. Simple math shows that we could all get fingolimod for about $14 a month if we were allowed to buy it that way. Based on their projected price of $4,000 a month, that’s a 285 times markup!
It is also my opinion that the $4,000 a month was figured by adding a thousand to the average $3,000 a month of the other therapies. They figure that no needles are worth $1,000 a month. The company line is that there is assistance available. Sure there is – if your family income is less than $30,000. Another company line is that insurance will cover most of the cost. With 40% of Americans not insured, I wonder how many people with MS aren’t able to afford any therapy at all. I have a co-pay with my insurance of 25%.
As much as I hate needles and as good as the product predicts to be, I suggest we all boycott Novartis’ Gilenya until they lower their price to at least $1,000 a month. That's still exorbitant but they do have the clinical trials to pay for - an estimated $25 million from what I've heard. There’s also the research money they paid out in advance to recoup.
In case you’re wondering, I use Copaxone and I have a $777.10 a month co-pay (25% of their “negotiated”cost). I did use Betaseron and got drug-induced Lupus and had to change. At least Betaseron uses the overies of Guniea pigs (in China) and that requires mfg. cost (and yuk!). I can almost see the large manufacturing cost for Betaseron but it looks like all of the other therapies base their price on Betaseron’s high price. I was infuriated with Copaxone ‘s price (soon to go generic) and really hoped that the new oral medication would be cheaper. When I found out the price I nearly stroked out. A cure that took maybe 12 months of treatment would be worth that, maybe, but the drug companies are really taking advantage of the fact that there is no cure and they’ve got us over a barrel.
Yes, I'm posting everywhere but y'all do the same and spread the word. Let's show Novartis’ Gilenya that people with MS are tougher than they think!
Post a Comment